MELAS with recurrent complex partial seizures, nonconvulsive status epilepticus, psychosis, and behavioral disturbances: Case analysis with literature review

Epilepsy and Behavior

Volumn 18, Issue 4, 2010, Pages 494-497

  Kaufman, Kenneth R ^a   Zuber, Nicole ^a   Rueda Lara, Maria A ^a   Tobia, Anthony ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Aggression; Coenzyme Q10; Complex partial seizures; Education; Levocarnitine; Mitochondrial encephalopathy; Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes (MELAS); Nonconvulsive status epilepticus; Oxidative stress; Paranoid delusions; Psychosis, hallucinations; Treatment; Valproate; Video EEG monitoring; Vitamin E

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTICONVULSIVE AGENT; ATORVASTATIN; CARNITINE; DOXYCYCLINE; GABAPENTIN; INSULIN; INSULIN LISPRO; ISOPHANE INSULIN; LORAZEPAM; MULTIVITAMIN; OLANZAPINE; PHENYTOIN; UBIDECARENONE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADD ON THERAPY; ADULT; AGGRESSIVENESS; AGITATED DEPRESSION; ARTICLE; AUDITORY HALLUCINATION; BEHAVIOR DISORDER; CASE REPORT; COMPLEX PARTIAL SEIZURE; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DELIRIUM; DIABETES MELLITUS; DISEASE COURSE; DISEASE DURATION; DISORIENTATION; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; ENCEPHALOMALACIA; EPILEPTIC STATE; GENETIC SCREENING; GRAND MAL SEIZURE; HOSPITALIZATION; HUMAN; LABORATORY TEST; LACTIC ACIDOSIS; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; MELAS SYNDROME; MOOD DISORDER; MORNING DOSAGE; MYOPATHY; NEUROPSYCHOLOGICAL TEST; NONCONVULSIVE EPILEPTIC STATE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSESSIVE COMPULSIVE DISORDER; PANIC; PARANOIA; PARTNER VIOLENCE; PERCEPTION DEAFNESS; PHOBIA; PROGNOSIS; PSYCHIATRIC TREATMENT; PSYCHOMOTOR RETARDATION; PSYCHOSIS; RECURRENT DISEASE; STROKE; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; VISUAL DISORDER;

ADULT; BEHAVIORAL SYMPTOMS; EPILEPSY, GENERALIZED; HUMANS; MALE; MELAS SYNDROME; SEIZURES;

EID: 77955576599     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2010.05.020     Document Type: Article

References (46)

1. Sproule D.M., Kaufmann P. Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotypes, and therapeutic management of MELAS syndrome. Ann NY Acad Sci 2008, 1142:133-158.
2. Uusimaa J., Moilanen J.S., Vainionpaa L., et al. Prevalence, segregation, and phenotype of the mitochondrial DNA 3243A>G mutation in children. Ann Neurol 2007, 62:278-287.
3. Manwaring N., Jones M.M., Wang J.J., et al. Population prevalence of the MELAS A3243G mutation. Mitochondrion 2007, 7:230-233.
4. Bhuvaneswar C.G., Goetz J.L., Stern T.A. Multiple neurologic, psychiatric and endocrine complaints in a young woman: a case discussion and review of the clinical features and management of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke. Prim Care Companion J Clin Psychiatry 2008, 10:237-244.
5. Kanaumi T., Hirose S., Goto Y., Naitou E., Mitsudome A. An infant with a mitochondrial A3243G mutation demonstrating the MELAS phenotype. Pediatr Neurol 2005, 34:235-238.
6. Higashikata T., Koyama J., Shimada H., Yazaki M., Owa M., Ikeda S. An 80-year-old mitochondrial disease patient with A3243G tRNA(Leu(UUR)) gene presenting with cardiac dysfunction as the main symptom. Intern Med 2001, 40:405-408.
7. Scaglia F., Northrop J.L. The mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options. CNS Drugs 2006, 20:443-464.
8. Finsterer J. Cognitive decline as a manifestation of mitochondrial disorders (mitochondrial dementia). J Neurol Sci 2008, 272:20-33.
9. Klopstock T., Jaksch M., Gasser T. Age and cause of death in mitochondrial diseases. Neurology 1999, 53:855-857.
10. Majamaa-Voltti K., Turkka J., Kortelainen M.-L., Huikuri H., Majamaa K. Causes of death in pedigrees with the 3243A>G mutation in mitochondrial DNA. J Neurol Neurosurg Psychiatry 2008, 79:209-211.
11. Fattal O., Budur K., Vaughan A.J., Franco K. Review of the literature on mental disorders in adult patients with mitochondrial diseases. Psychosomatics 2006, 47:1-7.
12. Barak Y., Arnon S., Wolach B., et al. MELAS syndrome: peripheral neuropathy and cytochrome C-oxidase deficiency: a case report and review of the literature. Isr J Med Sci 1995, 31:224-229.
13. Neargarder S.A., Murtagh M.P., Wong B., Hill E.K. The neuropsychological deficits of MELAS: evidence of global impairment. Cogn Behav Neurol 2007, 20:83-92.
14. Ribacoba R., Salas-Puig J., Gonzalez C., Astudillo A. Characteristics of status epilepticus in MELAS: analysis of four cases. Neurologia 2006, 21:1-11.
15. Alemdar M., Iseri P., Selckler M., Budak F., Demirci A., Sener S. MELAS presented with status epilepticus and Anton-Babinski syndrome; value of ADC mapping in MELAS. J Neuropsychiatry Clin Neurosci 2007, 19:482-483.
16. Leff A.P., McNabb A.W., Hanna M.G., Clarke C.R.A., Larner A.J. Complex partial status epilepticus in late-onset MELAS. Epilepsia 1998, 39:438-441.
17. Riggio S. Psychiatric manifestations of nonconvulsive status epilepticus. Mt Sinai J Med 2006, 73:960-969.
18. Feddersen B., Bender A., Arnold S., Klopstock T., Noachtar S. Aggressive confusional state as a clinical manifestation of status epilepticus in MELAS. Neurology 2003, 61:1149-1150.
19. Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Assoc, Washington, DC, Text rev. 4th ed.
20. Wyderski R.J., Starrett W.G., Abou-Saif A. Fatal status epilepticus associated with olanzapine therapy. Ann Pharmacother 1999, 33:787-789.
21. Woolley J., Smith S. Lowered seizure threshold on olanzapine. Br J Psychiatry 2001, 178:85-86.
22. Camacho A., Garcia-Navarro M., Martinez B., Villarejo A., Pomares E. Olanzapine-induced myoclonic status. Clin Neuropharmacol 2005, 28:145-147.
23. Alper K., Schwartz K.A., Kolts R.L., Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007, 62:345-354.
24. Corda D., Rosati G., Deiana G.A., Sechi G. "Erratic" complex partial status epilepticus as a presenting feature of MELAS. Epilepsy Behav 2006, 8:655-658.
25. Delgado-Escueta A.V., Mattson R.H., King L., et al. Special report: the nature of aggression during epileptic seizures. N Engl J Med 1981, 305:711-716.
26. Kanner A.M. Recognition of the various expressions of anxiety, psychosis, and aggression in epilepsy. Epilepsia 2004, 45(Suppl. 2):22-27.
27. Treiman D.M. Importance of early recognition and treatment of generalized convulsive status epilepticus. Lancet Neurol 2008, 7:667-668.
28. Eriksson K., Metsaranta H., Huhtala H., Auvinen A., Kuusela A.L., Koivikko M. Treatment delay and the risk of prolonged status epilepticus. Neurology 2005, 65:1316-1318.
29. Kaplan P.W. The clinical features, diagnosis, and prognosis of nonconvulsive status epilepticus. Neurologist 2005, 11:348-361.
30. Korff C.M., Nordli D.R. Diagnosis and management of nonconvulsive status epilepticus in children. Nat Clin Pract Neurol 2007, 3:505-516.
31. Maganti R., Gerber P., Drees C., Chung S. Nonconvulsive status epilepticus. Epilepsy Behav 2008, 12:572-586.
32. Cock H. The role of mitochondria in status epilepticus. Epilepsia 2007, 48(Suppl. 8):24-27.
33. Tan T.M., Caputo C., Medici F., et al. MELAS syndrome, diabetes, and thyroid disease: the role of mitochondrial oxidative stress. Clin Endocrinol (Oxf) 2009, 70:340-341.
34. Binienda Z., Przybyia-Zawisiak B., Virmani A., Schmued L. L-Carnitine and neuroprotection in the animal model of mitochondrial dysfunction. Ann NY Acad Sci 2005, 1053:174-182.
35. Kovacs R., Schuchmann S., Gabriel S., Kann O., Kardos J., Heinemann U. Free radical-mediated cell damage after experimental status epilepticus in hippocampal slice cultures. J Neurophysiol 2002, 88:2909-2918.
36. Zaja-Milatovic S., Gupta R.C., Aschner M., Montine T.J., Milatovic D. Pharmacologic suppression of oxidative damage and dendritic degeneration following kainic acid-induced excitotoxicity in mouse cerebrum. Neurotoxicology 2008, 29:621-627.
37. Sezen O., Ertekin M.V., Demircan B., et al. Vitamin E and L-carnitine, separately or in combination, in the prevention of radiation-induced brain and retinal damages. Neurosurg Rev 2008, 31:205-213.
38. Berbel-Garcia A., Barbera-Farre J.R., Etessam J.P., et al. Coenzyme Q 10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes). Clin Neuropharmacol 2004, 27:187-191.
39. Rodriguez M.C., MacDonald J.R., Mahoney D.J., Parise G., Beal M.F., Tarnopolsky M.A. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007, 35:235-242.
40. Treiman D.M., Meyers P.D., Walton N.Y., et al. A comparison of four treatments for generalized convulsive status epilepticus. N Engl J Med 1998, 339:792-798.
41. Misra U.K., Kalita J., Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology 2006, 67:340-342.
42. Wheless J.W., Treiman D.M. The role of the newer antiepileptic drugs in the treatment of generalized convulsive status epilepticus. Epilepsia 2008, 49(Suppl. 9):74-78.
43. Russell S. Carnitine as an antidote for acute valproate toxicity in children. Curr Opin Pediatr 2007, 19:206-210.
44. Lam C.W., Lau C.H., Williams J.C., Chan Y.W., Wong L.J. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr 1997, 156:562-564.
45. Lin C.M., Thajeb P. Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA. Metab Brain Dis 2007, 22:105-109.
46. Kaplan P.W. Nonconvulsive status epilepticus. Neurology 2003, 61:1035-1036.